Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 2, 1998, Pages 425-432

  Roa, Wilson H y ^a   Miller, Gerald G ^b   McEwan, Alexander J b ^a   McQuarrie, Steve A ^b   Tse, Jeanie ^a   Wu, Jonn ^a   Wiebe, Leonard I ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Dept of Radiol and Diagn Imaging University of Alberta ^*  (Canada)

Author keywords

125I mIBG; Dosimetry; Flow cytometry; Multicell spheroids; Neuroblastoma; Targeted radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; IODINE 125;

ARTICLE; CANCER RADIOTHERAPY; CELL KILLING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOSIMETRY; HUMAN; HUMAN CELL; ISOTOPE LABELING; NEUROBLASTOMA; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT INDICATION;

EID: 0032076754     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00061-3     Document Type: Article

References (46)

1. Young J.L. Jr, Ries L.G., Silverberg E., et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 58:1986;598-602.
2. Kun L. Childhood cancers. Moss W., Cox J. Radiation oncology rationale, technique, results . 1994;908-910 Mosby, St. Louis.
3. 131I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J. Nucl. Biol. Med. 35:1991;357-363.
4. Phillip T., Bernard J.L., Zucker J.M., et al. High-dose chemo-radiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma An unselected group of stage IV patients over 1 year of age . J. Clin. Oncol. 5:1987;266.
5. 131I-meta-iodobenzylguanidine therapy of neuroblastoma in childhood. Eur. J. Pediatr. 146:1987;246.
6. Evans A.E. Staging and treatment of neuroblastoma. Cancer. 45:1980;1799.
7. Smets A., Loesberg C., Janssen M., Metwally E.A., Husikamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 49:1989;2941-2944.
8. Jaques S. Jr, Tobes M.C., Sisson J.C., Baker J.A., Wieland D.M. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenodullary cells. Mol. Pharm. 26:1984;539-546.
9. Wheldon T. Targeted radiotherapy. Steel G.G. Basic clinical radiobiology. 1993;186-187 Edward Arnold Publisher, London.
10. Howell R.W., Narra V.R., Sastry K.S., Rao D.V. On the equivalent dose for Auger electron emitters. Radiat. Res. 134:(1):1993;71-78.
11. Sastry K.S. Biological effects of the Auger emitter iodine-125: A review. Report No. 1 of AAPM Nuclear Medicine Task Force Group No. 6. Med. Phys. 19:(6):1992;1361-1370.
12. Geselowitz D.A., McManaway M.E., Hofer K.G., Neumann R.D. The cytotoxicity of decays of tritium and iodine-125 incorporated in DNA of mammalian cells Implications for low-LET dosimetry of incorporated nuclides . Radiat. Res. 142:1995;321-326.
13. 125IUdR in mammalian cells Implications of localized energy deposition by auger processes . Radiat. Res. 109:1987;78-89.
14. Gaze M.N., Huxham I.M., Mairs R.J., Barrett A. Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. Int. J. Cancer. 47:1991;875-880.
15. Sisson J.C., Hutchinson R.J., Shapiro B., et al. Iodine 125-I-MIBG to treat neuroblastoma Preliminary report . J. Nucl. Med. 31:1990;1479-1485.
16. Sisson J.C., Shapiro B., Hutchinson R.J., Shulkin B.L., Zempel S. Survival of patients with neuroblastoma treated with 125-I MIBG. Am. J. Clin. Oncol. 19:(2):1996;144-148.
17. 125I decays in DNA Effect of cysteamine on micronucleus formation and cell killing . Radiat. Res. 141:1995;183-192.
18. Poyton R.O. Crosstalk between nuclear and mitochondrial genomes. Annu. Rev. Biochem. 65:1996;563-607.
19. 125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res. 48:1988;2993-2997.
20. Franko A.J., Sutherland R.M. Oxygen diffusion distance and development of necrosis in multicell spheroids. Radiat. Res. 79:1979;439-453.
21. Stuschke M., Budach V., Klaes W., Sack H. Radiosensitivity, repair capacity, and stem cell fraction in human soft tissue tumors An in vitro study using multicellular spheroids and the colony assay . Int. J. Radiat. Oncol. Biol. Phys. 23:1992;69-80.
22. 131I]iodobenzylguanidine. Appl. Radiat. Isotopes. 44:(3):1993;621-628.
23. Mairs R.J., Angerson W., Gaze M.N., Murray T., Babich J.W., Reid R., McSharry C. The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids. Br. J. Cancer. 63:1991;404-409.
24. Mairs R.J., Angerson W.J., Babich J.W., Murray T. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. Adv. Neuroblastoma Res. 3:1991;495-501.
25. Husain S., Allalunis-Turner J., Franko A., Parliament M., Poppema S. Tumor oxygenation in glioma xenografts Development of an automated image analysis system . Clin. Invest. Med. 18:(4):1995;800.
26. Loevinger R., Budinger T.F., Watson E.E. MIRD primer for absorbed dose calculations. 1991;Society of Nuclear Medicine, New York.
27. Goddu S.M., Rao D.V., Howell R.W. Multicellular dosimetry for micrometastases Dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides . J. Nuclear Med. 35:(3):1994;521-530.
28. Ediss C., Tam Y.K. An interactive program for determining areas bounded by drug concentration curves using lagrange interpolation. J. Pharmacol. Toxicol. Meth. 34:1995;165-168.
29. Goddu S.M., Howell R.W., Rao D.V. Cellular dosimetry Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments . J. Nuclear Med. 35:(2):1994;303-316.
30. Parks D.R., Lanier L.L., Herrenberg L.A. Flow cytometry and fluorescence activated cell sorting (FACS). Weir D.M. Handbook of experimental immunology. 1985;107-117 C. V. Mosby, St. Louis.
31. Biedler J.L., Helson L., Spengler B.A. Morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:1973;2643-2652.
32. Moore P.L., MacCoubrey I.C., Haugland R.P. A rapid, pH insensitive, two color fluorescence viability (cytotoxicity) assay. J. Cell Biol. 111:1991;58a.
33. Pawley J.B. Handbook of biological confocal microscopy. 1990;Plenum Press, New York.
34. SAS Institute Inc. SAS Proprietary software release 6.11. Cory, NC.
35. 2 block, and cell division. Radiat. Res. 124:1990;201-207.
36. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7):459-446; 1993.
37. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D.C., Fisher L.D., Bernstein I.D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329:(17):1993;1219-1224.
38. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 48:(11):1988;3270-3275.
39. 131I radiotherapy. Br. J. Cancer. 58:1988;658-662.
40. Stewart J.S.W., Hird V., Snook D., Sullivan M., Hooker G., Courtenay-Luck N., Sivolapenko G., Griffiths M., Myers M.J., Lambert H.E., Munro A.J., Epenetos A.A. Intraperitoneal radioimmunotherapy for ovarian cancer Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies . Int. J. Radiat. Oncol. Biol. Phys. 16:1989;405-413.
41. Nakano H., Shinohara K. X-ray-induced cell death Apoptosis and necrosis . Radiat. Res. 140:1994;1-9.
42. Yamada T., Ohyama H. Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int. J. Radiat. Biol. 53:1988;65-75.
43. Buchsbaum D.J., Langmuir V.K., Wessels B.W. Experimental radioimmunotherapy. Med. Phys. 20:1993;551-567.
44. 131I-labeled antibody in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;127-132.
45. Weber D.A., Eckerman K.F., Dillman L.T., Ryman J.C. MIRD Radionuclide data and decay scheme . 1989;Society of Nuclear Medicine, New York.
46. Howell R.W., Rao D.V., Hou D.Y., Narra V.R., Sastry K.S. The question of relative biological effectiveness and quality factor for auger emitters incorporated into proliferating mammalian cells. Radiat. Res. 128:1991;282-292.